Helical γ‐Peptide Foldamers as Dual Inhibitors of Amyloid‐β Peptide and Islet Amyloid Polypeptide Oligomerization and Fibrillization
Julia Kaffy, Corentin Berardet, Loïc Mathieu, Baptiste Legrand, Myriam Taverna, Frédéric Halgand, Guillaume van der Rest, Ludovic T. Maillard, Sandrine Ongeri
Abstract
Abstract Type 2 diabetes (T2D) and Alzheimer's disease (AD) belong to the 10 deadliest diseases and are sorely lacking in effective treatments. Both pathologies are part of the degenerative disorders named amyloidoses, which involve the misfolding and the aggregation of amyloid peptides, hIAPP for T2D and Aβ 1‐42 for AD. While hIAPP and Aβ 1‐42 inhibitors have been essentially designed to target β‐sheet‐rich structures composing the toxic amyloid oligomers and fibrils of these peptides, the strategy aiming at trapping the non‐toxic monomers in their helical native conformation has been rarely explored. We report herein the first example of helical foldamers as dual inhibitors of hIAPP and Aβ 1‐42 aggregation and able to preserve the monomeric species of both amyloid peptides. A foldamer composed of 4‐amino(methyl)‐1,3‐thiazole‐5‐carboxylic acid (ATC) units, adopting a 9‐helix structure reminiscent of 3 10 helix, was remarkable as demonstrated by biophysical assays combining thioflavin‐T fluorescence, transmission electronic microscopy, capillary electrophoresis and mass spectrometry.